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To determine the possible role of atrial natriuretic factor in 
right ventricular infarction, serial measurements of this 
hormone were performed in 21 patients with acute inferior 
myocardiai infarction. All patients underwent enzymatic, 
electrocardiographic, echocardiographic and coronary ar- 
teriographic studies. Ten patients also had right heart 
hemodynamic measurements. Eight patients had evidence 
of an associated right ventricular infarction (Group I) and 
13 patients did not (Group II). Enzymatically estimated 
infarct size, presence of left heart failure and arrhythmias 
were similar in both groups. Mean arterial pressure in 
Group I (72.1 f 4.4 mm Hg) was significantly lower (p = 
0.02) than in Group II (89.5 f 4.6 mm Hg). Seven (88%) of 
the eight patients in Group I had elevated right atria1 
pressures and a higher incidence than Group II of pro- 
longed hypotension (75%) and right ventricular dysfunc- 
tion (75%) clinically and by echocardiography. 
Plasma atrial natriuretic factor levels (mean values & 
SEM in pg/mI) for days 1, 2,3 and 7 after infarction were, 
respectively: 152 f 30,165 f 48,199 f 27 and 189 f 31 for 
Group I versus 55 & 9,55 + 11, 61 f 13 and 77 + 20 for 
Group II. The difference between groups was significant for 
days 1 (p < 0.05), 3 and 7 (p < 0.01) and not significant for 
day 2 (p = 0.07). These findings show that atrial natriuretic 
factor elevation is part of the neurohumoral response to 
right ventricular infarction and are consistent with the 
hypothesis that atria1 natriuretic factor may play a patho- 
physiologic role in the right ventricular infarct syndrome. 
(J Am Co11 Cardiol1990;15:546-53) 
Right ventricular infarction occurs almost exclusively as a 
complication of inferoposterior left ventricular infarction 
(1,2), and its manifestations range from asymptomatic right 
ventricular dysfunction to the classic clinical and hemody- 
namic syndrome of predominant right ventricular failure 
described by Cohn et al. (3). The hemodynamic findings in a 
given patient with right ventricular infarction depend on the 
extent of necrosis of the right ventricle, the degree of left 
ventricular dysfunction, the function of the interventricular 
septum and the competence of the tricuspid valve (4), as well 
as on the maintenance of atrioventricular (AV) conduction 
and the interaction of different neurohumoral stimuli. To our 
knowledge, the role of atria1 natriuretic factor in this condi- 
tion has not been previously studied. 
Because increases in right atria1 pressure (a common 
occurrence in right ventricular infarction) (3,5-7) are asso- 
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ciated with elevation of plasma atria1 natriuretic factor 
(8-13), we postulated that the latter may be disproportion- 
ately elevated in patients with right ventricular infarction, 
compared with patients with inferior myocardial infarction 
without right ventricular involvement. If so, atria1 natriuretic 
factor, a peptide with significant natriuretic and vasorelaxant 
(hypotensive) effects, could play a pathophysiologic role in 
the development of the right ventricular infarction syndrome 
of high right heart filling pressures, depressed cardiac output 
and vasodilation with hypotension. We designed this pro- 
spective study of inferior myocardial infarction to investi- 
gate this hypothesis and to try to determine any possible 
contribution of atria1 natriuretic factor to the early diagnosis 
of right ventricular infarction, which is known to be impor- 
tant from both therapeutic and prognostic standpoints. 
Methods 
Study patients. Between February 1987 and June 1988, 
all the patients admitted to the coronary intensive care unit 
of the Cleveland Clinic Hospital within 24 h of an acute 
inferior myocardial infarction were screened for inclusion in 
the study. Patients with one or more of the following 
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conditions were excluded: 1) history of congestive heart 
failure; 2) chronic atria1 tachyarrhythmias; 3) previous myo- 
cardial infarction; 4) successful percutaneous transluminal 
coronary angioplasty or thrombolytic therapy during the first 
6 h of the myocardial infarction (manifested by electrocar- 
diographic [ECG] or angiographic evidence of myocardial 
reperfusion); 5) valvular heart disease; 6) chronic pericardial 
disease; 7) car pulmonale; 8) chronic renal failure; and 9) 
complete left bundle branch block. All of these conditions 
are associated with abnormal plasma atria1 natriuretic factor 
levels or baseline ECG abnormalities that would have made 
the interpretation of our results difficult. All patients gave 
informed consent for inclusion in the study. The protocol 
was approved by the Research Programs Committee of the 
Cleveland Clinic Foundation. 
Laboratory studies. All patients had serial 12 lead ECGs 
and measurement of cardiac enzymes. Right-sided ECG V 
leads (V,, to V& and back leads (V,, Vs, V,) were 
recorded on admission. M-mode and two-dimensional echo- 
cardiography were performed within 48 h of admission 
(using Hewlett-Packard 77020 AC/AR or Johnson & Johnson 
Irex-Meridian machines with 2.5 to 3.5 MHz transducers). 
Right-sided V leads and echocardiograms were repeated if 
there was a deterioration in the clinical status of a previously 
stable patient (such as recurrent angina, hypotension, AV 
block or new ECG signs different from those of an inferior 
infarction in evolution). 
Left heart catheterization and coronary arteriography 
were performed during the patient’s admission using the 
Sones or Judkins technique. A severe coronary artery ste- 
nosis was considered present if there was ~70% luminal 
obstruction. Patients with hypotension (systolic blood pres- 
sure 00 mm Hg), jugular venous distension, left ventricular 
failure or ECG or echocardiographic evidence of right ven- 
tricular infarction, as defined below, had hemodynamic 
monitoring using a Swan-Ganz thermodilution catheter. 
Right atrial, right ventricular, pulmonary artery, and pulmo- 
nary capillary wedge pressures were continuously recorded 
with a Horizon 2000 system (Mennen Medical). Cardiac 
index and systemic vascular resistance were calculated by 
standard formulas. 
Plasma atria1 natriuretic factor levels were measured on 
days I, 2, 3 and 7 of the acute myocardial infarction by a 
radioimmunoassay technique developed in our laboratory. 
Two milliliters of blood was collected in chilled polyethylene 
tubes containing 2,000 Kallikrein inactivated units (KIU) 
aprotinin and 2 mg ethylenediaminetetraacetic acid (EDTA). 
Blood was centrifuged at 1,500 g for 15 min at 4”C, and 
plasma was stored frozen at -70°C until assay. Plasma was 
usually assayed within 1 week after collection. Samples from 
each set of experiments were analyzed as a batch to mini- 
mize day-to-day variability in the assay. Plasma was ex- 
tracted using Bond Elut columns (Analytichem Internation- 
al). Normal values are 30.4 ? 2.5 pg/ml (mean 2 SE) in 
fasting, supine subjects at rest consuming a normal amount 
of dietary sodium. 
The interpretation of the ECGs and echocardiograms, as 
well as the atria1 natriuretic factor measurements, was done 
by observers who did not know the result of any other test in 
the patient. 
All the patients had strict fluid intake and output record- 
ing during the first 3 days after infarction or longer if 
clinically indicated. Clinical complications were recorded in 
each patient. 
Diagnostic criteria. Inferior myocardial infarction was 
diagnosed if the patient developed new pathologic Q waves 
(>40 ms in duration) in at least two inferior ECG leads, 
associated with above normal increases in total creatine 
kinase and its MB fraction. The diagnosis of posterior 
infarction was made in the presence of R waves greater than 
S waves in lead V, and pathologic Q waves in the back V 
leads; and of right ventricular infarction if. in addition to 
having an inferior myocardial infarction, the patient met at 
least two of the following criteria: 1) ST segment elevation of 
at least 0.5 mm (measured 80 ms after the J point) in leads 
V 3R7 &R Or v5Ui 2) echocardiographic evidence of right 
ventricular dilation or dysfunction, or both (segmental or 
global wall motion abnormalities); 3) coronary arteriograms 
showing occlusion of the right coronary artery proximal to 
its right ventricular branches. 
Overall right and left ventricular function by echocardio- 
graphic and, when available, ventriculographic studies was 
classified as normal or abnormal. Ventricular dysfunction 
was further classified as mild, moderate or severe. In pa- 
tients with hemodynamic studies, the criterion for diagnos- 
ing right ventricular infarction was a mean right atria1 
pressure greater than, equal to or 1 to 5 mm Hg lower than 
the pulmonary capillary pressure, or a right atria1 pressure 
waveform showing a y descent equal to or greater than the x 
descent (14,15). 
Statistical analysis. Results in patient study groups were 
expressed as mean values ? SEM, and statistical compari- 
sons were made across groups using Student’s t test. Fish- 
er’s exact test was used to compare the clinical characteris- 
tics of the two groups. Pearson’s correlation coefficient was 
employed to examine the relation between atria1 natriuretic 
factor levels and other variables, including right atria1 pres- 
sure, pulmonary capillary wedge pressure, cardiac index, 
systemic vascular resistance, urinary output, ratio of urinary 
output to intake, peak serum creatine kinase levels, and peak 
serum creatine kinase MB levels; p values <0.05 were 
considered significant. 
Results 
Clinical patient features. Over the time course of this 
study, 112 patients were admitted to our coronary care unit 
with the diagnosis of acute inferior myocardial infarction. 
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Ninety-one of these patients were excluded for the following 
reasons: 39 had successful coronary angioplasty or throm- 
bolytic therapy during the first 6 h of the infarction, 21 had a 
history of a previous inferior infarction, 20 had a history of 
congestive heart failure, 6 were admitted >24 h from the 
onset of chest pain, 4 had end-stage renal disease, and 1 
underwent coronary artery bypass grafting on the day of 
admission, 
0.0001) and day 7 (p = 0.0055). The difference for day 2 had 
a borderline p value (0.07). 
The remaining 21 patients were included in the final 
analysis; all of these patients had ECG and enzymatic 
evidence of an acute inferior myocardial infarction, and 8 of 
them (38%) also had evidence of right ventricular involve- 
ment. No significant differences were found between pa- 
tients with (Group I, n = 8) and without right ventricular 
infarction (Group II, n = 13) for any of the following clinical 
features: age (mean 57.4 years for Group I and 50.9 years for 
Group II), gender, hypertension, diabetes mellitus, hyper- 
cholesterolemia, cigarette smoking, previous coronary by- 
pass surgery or unsuccessful thrombolytic therapy or coro- 
nary angioplasty on the day of admission. 
Electrocardiography. As previously described, all pa- 
tients had ECG signs of an acute inferior myocardial infarc- 
tion. Evidence of an associated posterior infarction was 
encountered in six patients (75%) from Group I and in five 
patients (38%) from Group II. ST segment elevation of 0.5 
mm or more in lead V,, was seen in all the patients in Group 
I and in 2 of the 13 patients in Group II (Table 1). 
Hemodynamic studies. Hemodynamic evaluation was 
performed in all the patients of Group I (Table 3) and in two 
of Group II. Mean arterial pressure on admission in Group I 
(72.1 ? 4.4 mm Hg) was significantly lower (p = 0.02) than 
that in Group II (89.5 ? 4.6 mm Hg). In Group I, pressures 
on the day of admission were as follows: 15.4 2 1.5 in the 
right atrium (88% had mean right atria1 pressures 212 mm 
Hg); 30.9 + 2.7 (systolic) and 17.6 + 1.9 (diastolic) in the 
pulmonary artery; and 14.6 + 1.9 in the pulmonary capillary 
wedge position. In the same group, the cardiac index was 
2.3 + 0.4 liters/min per m2 and systemic vascular resistance 
2,242 2 352.1 dynescm-5. In Group II, pressures on the 
same day were 12.5 +- 2.5 in the right atrium, 34.5 t 4.5 
(systolic) and 18.5 + 0.5 (diastolic) in the pulmonary artery, 
and 19.0 f 2.0 in the pulmonary wedge position. The cardiac 
index was 2.05 ? 0.1 literslmin per m* and systemic vascular 
resistance was 1,209.O ? 151.0 dynescm-‘. Because only 
two patients (those with significant hemodynamic compro- 
mise) had hemodynamic measurements in Group II, a sta- 
tistical comparison between the groups was not performed. 
Echocardiography. Regional or global right ventricular 
wall motion abnormalities were seen in six patients of Group 
I and in none of Group II. Some degree of left ventricular 
dysfunction was observed in four patients of Group I (one of 
mild and three of moderate-to-severe degree) and in six 
patients of Group II (four of mild and two of moderate 
severity) (Table 1). 
Cardiac enzymes. Mean values ? SEM for peak creatine 
kinase in IU/liter were 3391.8 2 385.0 for Group I and 1924.8 
-t 509.1 for Group II (p = 0.05 for the difference between 
groups). Peak creatine kinase MB results in IUlliter were 
221.9 ? 83.9 in Group I and 276 + 86.6 in Group II (p = 
0.21). 
Coronary arteriography. Angiographic studies were per- 
formed in all patients. In Group I, six patients (75%) had 
angiograms in the first 48 h of the infarction, and two had 
them 1 month later. In Group II, the coronary arteriograms 
were done within 72 h in nine patients (69%) and in all within 
11 days of the infarction (mean 3.7 days). A right coronary 
artery occlusion or severe stenosis was seen in all patients in 
Group I and in 11 (85%) of the 13 patients in Group II. The 
right coronary artery lesion was proximal to its right ven- 
tricular branches in seven (88%) of the eight patients of 
Group I and in two (15%) of Group II. The incidence of 
single, double and triple vessel coronary artery disease was, 
respectively, 50%, 37.5% and 12.5% in Group I and 46%, 
39% and 15% in Group II (Table 1). Because of hemody- 
namic instability at the time of the study, five patients in 
Group I and one in Group II did not have a ventriculogram. 
Fluid intake and output. Patients in Group I had higher 
fluid intake than Group II in each of the first 3 days following 
infarction. Mean fluid intake in ml for Groups I and II were, 
respectively, 3,528 versus 2,059 on day 1,4,226 versus 2,453 
on day 2 and 2,686 versus 2,008 on day 3. However, only on 
day 2 was the difference significant (p = 0.03). The mean 
cumulative intake for these days was 9,581 ml for Group I 
and 6,251 ml for Group II (p = 0.09). The mean cumulative 
urinary output for the same days was 5,358 ml for Group I 
and 6,024 ml for Group II. Neither this difference nor the 
ones for daily outputs were statistically significant. 
Correlations between atrial natriuretic factor and other 
variables. The following correlations were performed over- 
all and by groups: atria1 natriuretic factor levels on days 1 
and 2 with peak creatine kinase and peak creatine kinase MB 
values; atria1 natriuretic factor levels on days 1, 2 and 3, and 
urinary output and the ratio between urinary output/fluid 
intake for the same days; atria1 natriuretic factor levels on 
day 1 with right atrial, pulmonary capillary wedge and mean 
systemic arterial pressures, cardiac index and systemic 
vascular resistance. None of these correlations was found to 
be significant. 
AtriaI natriuretic factor levels (Table 2). Group I had a Complications. In Group I (right ventricular infarction), 
much greater elevation of atria1 natriuretic factor than did six patients had hypotension unresponsive to intravenous 
Group II (Fig. 1). The difference between groups was fluids, two patients developed clinical left heart failure and 
statistically significant for day 1 (p = 0.02), day 3 (p = one died after biventricular failure with cardiogenic shock 
JACC Vol. 15, No. 3 ROBALINO ET AL. 549 
March 1, 1990546-53 NATRIURETIC PEPTIDE IN RIGHT VENTRICULAR INFARCTION 
Table 1. Results of Electrocardiographic (ECG), Echocardiographic and Angiographic Studies, and Complications in 8 Patients With 
Right Ventricular Infarction (Group I) and 13 Without Right Ventricular Infarction (Group II) 
Age 
(yr)i 
Gender 
ECG Echocardiogram Angiogram 
VR Back RV LV Vessels LV 
Leads Leads Dysfunction Dysfunction Involved Dysfunction Complications 
Group 1 
1 39/M 
2 50/M 
3 15iF 
4 59/M 
5 70/F 
6 64/M 
7 54iF 
8 48/M 
Group II 
1 
2 
3 
4 
5 
6 
48/M 
45iM 
54/M 
SO/M 
59/M 
63/M 
7 50/M 
8 26/M 
9 53/F 
10 50/M 
11 46/M 
12 56/F 
13 62lM 
+ 
+ 
t 
t 
t 
t 
t 
t 
t 
t 
_ 
- 
_ 
- 
_ 
_ 
_ 
_ 
_ 
t 
t 
t 
t 
_ 
t 
t 
_ 
- 
t 
_ 
+ 
t 
_ 
t 
_ 
_ 
t 
Moderate Mild RCA-P. LCx NA 
Severe Severe RCA-P. LAD, LCx NA 
Mild Moderate RCA-D, LAD NA 
Mild 
_ 
_ RCA-P, LCx Mild 
RCA-P NA 
_ _ RCA-P NA 
Mild Moderate RCA-P, LCx Moderate 
Mild RCA-P _ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
Mild 
Mild 
Moderate 
Mild 
_ 
RCA-D, LAD 
RCA-D 
RCA-P, LAD 
RCA-D, LAD, LCx 
RCA-D 
RCA-D 
NA 
Moderate 
Moderate 
Moderate 
Mild 
_ LCX 
_ RCA-D, LAD 
_ RCA-D 
Mild RCA-P. LCx 
_ 
_ 
Mild 
_ RCA-D, LAD, LCx _ 
_ RCA-D, LAD Mild 
Mild LCX Mild 
Hypotension (day I), 
LHF (day 2) 
LHF and RHF (day l), CHB 
(day I). died (day 2) 
Transient CHB (day l), 
hypotension (day I), 
LHF (day 4) 
_ 
Hypotension (day 1). 
transient CHB (day 1) 
Prolonged AV dissociation 
(dd)‘S 2, 3) 
Hypotension (day I), 
prolonged AV dissociation 
(days 1 to 5) 
Hypotension (day I) 
LHF (day 4) 
Hypotension (day 1). 
recurrent SVT (day 6) 
_ 
Prolonged AV dissociation 
(day 3) 
Hypotension (day I). 
LHF (day 2) 
AV = atrioventricular; CHB = complete heart block; F = female; LAD = left anterior descending artery; LCx = left circumflex artery; LHF, RHF = left 
and right heart failure, respectively; LV = left ventricle; M = male; NA = not available; RCA-P, D = right coronary artery, proximal (P) or distal (D) to its right 
ventricular branches; RV = right ventricle: SVT = supraventricular tachycardia: VR = right precordial leads; (t) = positive; (-) = negative or not present. 
(the only death in the two groups). There were also two 
patients with prolonged AV dissociation (>12 h) in this 
group. In Group II, two patients had hypotension requiring 
vasopressor therapy, two developed left heart failure, one 
had late recurrent supraventricular tachycardia and one had 
AV dissociation (Table 1). 
Discussion 
Right ventricular infarction syndrome. In patients with 
inferopostetior myocardial infarction, right ventricular in- 
volvement occurs in up to 43% by autopsy (4); however, it is 
clinically evident in only about 19% of them (16). Some of 
these patients develop the right ventricular infarction syn- 
drome originally described by Cohn et al. (3) and character- 
ized by elevated right heart filling pressures that exceed left 
heart pressures, distended neck veins, heart block and 
hypotension responding to plasma volume expansion. Sub- 
sequent investigations have shown that these patients often 
have inappropriate natriuresis and protracted hypotension, 
sometimes in the setting of normal left ventricular function. 
Dysfunction of the right ventricle cannot explain all these 
manifestations entirely. As mentioned before, several mech- 
anisms have been proposed to explain the hemodynamic 
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Table 2. Plasma Atria1 Natriuretic Factor (ANF) Levels Following Inferior Myocardial Infarction in 8 Patients With (Group I) and 13 
Without (Group II) Associated Right Ventricular Infarction 
Atrial Natriuretic Factor (pg/ml) 
Group I Group II 
Patient Day 1 Day 2 Day 3 Day I Patient Day 1 Day 2 Day 3 Day I 
1 119.3 147.7 136.2 132.6 1 9.6 19.7 23.4 11.5 
2 120.5 19.1 Expired 2 5.2 16.3 21.8 12.4 
3 141.3 301.1 199.9 165.0 3 44.8 70.7 36.9 25.5 
4 - - 149.1 336.3 4 67.0 85.2 93.8 170.0 
5 - - 153.0 155.1 5 40.1 16.4 94.1 81.3 
6 243.4 173.9 319.2 162.6 6 35.8 35.3 - 119.2 
7 232.8 292.6 275.0 271.0 7 67.2 37.7 13.7 162.7 
8 53.3 56.7 158.0 103.0 8 29.6 30.8 69.1 - 
9 90.6 67.5 40.7 24.7 
Mean t SEM 151.8 t 29.9* 165.2 f 47.7 198.6 t 26.9t 189.4 + 31.4t 10 - 82.8 96.7 58.7 
I1 96.6 - 31.2 27.4 
12 93.6 61.5 37.7 29.5 
13 80.7 140.4 172.2 201.6 
Mean 2 SEM 55.1 + 9.3 55.4 k 10.6 61.0 f 13.3 77.0 t 19.9 
*p < 0.05, tp < 0.01, p = 0.07 versus Group II. 
derangements seen in these patients. We hypothesized that to 94% predictive accuracy to detect right ventricular infarc- 
atria1 natriuretic factor might be another contributing vari- tion diagnosed by scintigraphic, hemodynamic or postmor- 
able in this distinctive syndrome. tem studies (33-37). Two-dimensional echocardiography is 
Atrial natriuretic factor in heart disease. Atria1 natriuretic 
factor is released into the circulation in response to increases 
in atria1 pressure leading to stretch. Its main effects are 
diuresis and natriuresis, inhibition of the renin-aldosterone 
axis at different levels and hypotension (17). The acute 
hypotension associated with this peptide results from the 
extravasation of fluid it induces and from its potent vasore- 
laxant properties leading to venodilation and decreased 
cardiac output (18). More long-term effects on blood pres- 
sure are based on its renal effects and its interactions with 
other hormones and the autonomic nervous system (18). 
Figure 1. Mean plasma atria1 natriuretic factor (ANF) levels in 
patients with inferior myocardial infarction. Patients (Pts) with 
associated right ventricular infarction (RVI) had a significantly 
greater ANF elevation during the first week following infarction, 
except on day 2. 
0 
Plasma atria1 natriuretic factor is elevated in heart failure 
(10,19-21), supraventricular tachyarrhythmias (22-24), arte- 
rial hypertension (25-27), and acute and old myocardial 
infarction (12,28-31). We have also found high levels of this 
hormone in patients with unstable angina and ST segment 
elevation not progressing to myocardial infarction (unpub- 
lished data). The common denominator in these diverse 
cardiovascular conditions is an increase in right or left atrial 
pressure promoting the secretion of atria1 natriuretic factor 
(32). 
0 
0 
The current study. To explore the hypothesis that atria1 
natriuretic factor could be disproportionately elevated in 
right ventricular infarction, we measured plasma levels of 
this peptide in 21 patients with acute inferior myocardial 
infarction. All patients were evaluated prospectively by 
diagnostic techniques of proved value in right ventricular 
infarction. Thus, ST segment elevation ~0.5 mm in lead V,R 
is 76% to 100% sensitive, 68% to 86% specific and has a 67% 
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Table 3. Initial Hemodynamic Measurements in All Eight Patients With Right Ventricular Infarction (Group I) 
Patient RAP PAP-S 
Pressures (mm Hg) 
PAP-D PCWP MAP 
Cl 
(litersimin per m’) 
SVR 
(dyne s-cm-? 
I 17 33 21 I7 79 2.1 1.396 
2 18 39 21 I? 79 2.3 1,380 
3 20 36 23 20 71 1.1 3,012 
4 I6 32 16 14 65 1.8 2.800 
5 20 36 23 22 63 - - 
6 12 33 I5 I4 97 - 
7 12 21 I4 13 60 1.4 1,632 
8 8 17 8 5 63 4.2 3.234 
Mean + SEM 15.4 t I.5 30.9 ? 2.7 17.6 ? 1.9 14.6 ? I.9 72.1 + 4.4 2.25 ? 0.4 2.242 + 352.1 
CI = cardiac index; MAP = mean systemic arterial pressure; PAP-D, S = pulmonary artery pressure in diastole and systole, respectively: PCWP = pulmonary 
capillary wedge pressure; RAP = mean right atrial pressure; SVR = systemic vascular resistance. 
very helpful in detecting ischemic right ventricular wall 
motion abnormalities (38-41) especially when hemodynam- 
ically consequential (38), and is 82% sensitive and 93% 
specific to diagnose right ventricular infarction demonstrated 
by scintigraphy (42). Coronary arteriography reveals that 
right ventricular infarction occurs almost exclusively with 
occlusion of the right coronary artery proximal to its right 
ventricular branches (35,43). By combining these three di- 
agnostic methods (electrocardiography, echocardiography 
and coronary arteriography), we believe that it is unlikely 
that we have missed or misdiagnosed a case of clinically 
significant right ventricular infarction. Supporting this is the 
fact that the presence or absence of this condition by our 
criteria was confirmed in all the patients who had hemody- 
namic studies (eight with and two without right ventricular 
infarction). 
The results of’ plasma atria1 natriuretic factor determina- 
tions support our initial hypothesis. In patients with right 
ventricular infarction (Group I), mean atria1 natriuretic fac- 
tor levels exceeded 150 pglml, representing a sixfold in- 
crease over normal with some determinations in this group 
approaching those seen in patients with severe congestive 
heart failure (13.19) or who have received pharmacologic 
doses of atria1 natriuretic factor intravenously (18). In con- 
trast, patients without right ventricular infarction (Group II) 
averaged approximately twice the normal values for the 
peptide. The differences in these levels between the two 
groups were statistically significant, except for day 2, when 
a borderline p value was obtained as a result of one normal 
value in Group I. a second determination in a patient with an 
earlier level of 121 pg/ml, obtained shortly before his death. 
This was the only patient in our study in whom atria1 
natriuretic factor showed a precipitous fall from one day to 
the next, and it occurred in the setting of profound biven- 
tricular failure. At autopsy, this patient had a massive 
infarction involving the inferoposterior wall of the left ven- 
tricle and almost the entire right ventricle. Although we do 
not have a clear explanation for this normal premortem atrial 
natriuretic factor level, in addition to laboratory error, the 
possibility of atria1 natriuretic factor depletion after an initial 
large release may be considered. Plasma atria1 natriuretic 
factor decreases after an initial elevation during acute myo- 
cardial infarction (29). One study (30) showed bimodal 
elevation of this peptide in 23 patients having an acute 
myocardial infarction. An early peak level (mean 51 pg/ml) 
occurred 8 h after the onset of pain, followed by a trough 
(mean 25.9 pgiml), and a second peak at 44 h after infarction 
(mean 63.8 pgiml). Location of the infarction (anterior or 
inferior) does not influence atrial natriuretic factor levels 
(30,31). 
A markedly elevated plasma atria1 natriuretic factor as an 
independent measure correlated well with the occurrence of 
right ventricular infarction: 82% of all levels over 100 pglml 
in the study, as well as 100% of the measurements above this 
value on day 1, were seen in Group I (the right ventricular 
infarction group). Furthermore, only three levels were below 
100 pgiml in this group. Thus, in the initial phase of an 
inferior infarction, a peripheral plasma atria1 natriuretic 
factor level above 100 pglml could be a simple inexpensive 
way of confirming the presence of right ventricular infarc- 
tion, especially if faster results of the assay become avail- 
able. 
As expected, patients in Group 11 (no right ventricular 
infarction) developing supraventricular tachyarrhythmias, 
prolonged episodes of AV block and left heart failure tended 
to have higher atria1 natriuretic factor values on day 7 after 
infarction, but even then, the levels in Group I were still 
significantly higher (p = 0.005). The hemodynamic effects of 
high plasma atria1 natriuretic factor levels 1 week postinfarc- 
tion are more likely to be counterbalanced by other factors 
involved in fluid and blood pressure homeostasis, which 
were mentioned before. 
Causes of elevated atria1 natriuretic factor in right ventric- 
ular infarction. Atria1 natriuretic factor levels did not corre- 
late with right atria1 or mean systemic arterial pressures, 
probably because blood sampling and pressure measurement 
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were not always done simultaneously. However, as a group, 
the patients with right ventricular infarction (Group I) had 
higher right atria1 pressure, lower systemic pressure, and a 
greater incidence of clinical and echocardiographic evidence 
of right ventricular dysfunction. Peak creatine kinase MB, 
presence of clinical left heart failure and supraventricular 
tachyarrhythmias were similar in both groups. Peak creatine 
kinase values were higher in Group I, although this only 
achieved borderline statistical significance. Previous studies 
(44) have demonstrated higher release of creatine kinase in 
inferior infarction with right ventricular involvement, but 
there are also investigations not corroborating this (45). 
Complete heart block was seen in two patients of Group I, 
and in none of Group II. Nevertheless, the episodes of 
complete heart block were transient and present only on the 
day of the infarction, which could not explain prolonged 
elevations of atrial natriuretic factor. Therefore, we think 
that right heart dysfunction and dilation (as documented by 
our echocardiographic and hemodynamic data), leading to 
high filling pressures and stretch of the right atrium, are 
among the main factors responsible for the markedly ele- 
vated atria1 natriuretic factor levels seen in right ventricular 
infarction. Although not especially looked for in this study, 
right atria1 infarction, which occurs in 35% of cases of right 
ventricular infarction (46), could also be a contributing factor 
for atria1 natriuretic factor release. 
We did not find a correlation between atria1 natriuretic 
factor levels and urinary output. Nonetheless, we cannot 
draw any conclusion about the diuretic effect of atria1 
natriuretic factor in our patients, because the administration 
of intravenous fluids, diuretics and contrast dye was not the 
same in all of them. 
Possible pathophysiologic role of atrial natriuretic factor in 
right ventricular infarction. Although one might speculate 
that the markedly elevated atria1 natriuretic factor levels in 
right ventricular infarction are mere epiphenomena related 
to the high right filling pressures and resultant right atria1 
stretch, elevated levels of this peptide could carry an impor- 
tant biologic effect. Vasorelaxation, vagal afferent stimula- 
tion and increased glomerular filtration caused by higher 
levels of atria1 natriuretic factor may be detrimental to a 
heart with normal left ventricular function, leading to de- 
creased left ventricular filling pressures and hypotension. A 
vicious cycle would be set up in which higher atria1 natri- 
uretic factor levels would require more volume infusion to 
maintain filling pressures, with the risk of greater distension 
of the right heart chambers, leading to more secretion of the 
peptide. In six of our eight Group I patients with right 
ventricular infarction, vasopressors were required for the 
treatment of hypotension unresponsive to fluid administra- 
tion. Thus, it is tempting to hypothesize that the secretion of 
atria1 natriuretic factor by the distended right atrium would 
be beneficial in the setting of left ventricular dysfunction, but 
detrimental in the face of normal left ventricular filling 
pressures. 
Although the clinical presentation of right ventricular 
infarction is dependent on many variables, the relatively 
small number of patients involved in this study permits us 
only to speculate about the possible pathophysiologic role of 
atria1 natriuretic factor in this condition. The role of other 
factors that could interact with atria1 natriuretic factor and 
lead to natriuresis and diuresis, such as decreased aldoste- 
rone or antidiuretic hormone, or diminished renal sympa- 
thetic tone, also needs to be clarified. 
Conclusions. This prospective study shows that a pro- 
nounced atria1 natriuretic factor elevation is part of the 
neurohumoral response to right ventricular infarction. Pa- 
tients with inferior infarction and no right ventricular in- 
volvement also have increased levels of this peptide, but to 
a much lesser extent. The elevation of atria1 natriuretic 
factor in right ventricular infarction is probably secondary to 
the dilation and elevation of pressures in right-sided heart 
chambers seen in this condition, because it occurs even in 
the absence of the common cardiovascular entities associ- 
ated with elevation of this peptide. In an acute inferior 
infarction, a high plasma atria1 natriuretic factor level (> 100 
pglml) may be used as an early diagnostic marker of right 
ventricular involvement and could be considered another 
variable that explains the multifactorial hypotension seen in 
some of these patients. Atria1 natriuretic factor may, there- 
fore, play a pathophysiologic role in the right ventricular 
infarction syndrome. Further studies are needed to verify 
this hypothesis, as well as to determine the diagnostic and 
prognostic value of atria1 natriuretic factor levels in this 
syndrome. 
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